Nose Kozue, Taniguchi Keiko, Fujita Mitsugu, Moyama Chiami, Mori Masaya, Ishita Mizuki, Yoshida Tatsushi, Ii Hiromi, Sakai Toshiyuki, Nakata Susumu
Laboratory of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan.
Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Cancer Gene Ther. 2024 Dec;31(12):1831-1839. doi: 10.1038/s41417-024-00835-y. Epub 2024 Oct 11.
Glioblastoma stem cells (GSCs) have been reported to cause poor prognosis of glioblastoma by contributing to therapy resistance. γ-Glutamylcyclotransferase (GGCT) is highly expressed in various cancer types, including glioblastoma, and its inhibition suppresses cancer cell growth. However, the mechanism of GGCT overexpression and its function in GSCs are unknown. In this study, we show that GGCT is highly expressed in GSCs established from a mouse glioblastoma model and its knockdown suppresses their proliferation. Effects of NRas and its downstream transcription factor c-Jun on GGCT expression were analyzed; NRas knockdown reduced c-Jun and GGCT expression. Knockdown of c-Jun also reduced expression levels of GGCT and inhibited cell proliferation. Consistent with this, pharmacological inhibition of c-Jun with SP600125 reduced GGCT and inhibited GSC proliferation. Furthermore, the GGCT promoter-reporter assay with mutagenesis demonstrated that c-Jun regulates the activity of the GGCT promoter via AP-1 consensus sequence. Gene expression analysis revealed that GGCT knockdown showed a repressive effect on the Delta-Notch pathway and decreased Notch1 expression. Notch1 knockdown alone inhibited the GSC proliferation, confirming that Notch1 is functional in this model. Forced expression of the Notch1 intracellular domain restored the growth inhibitory effect of GGCT knockdown. Moreover, GGCT knockdown inhibited GSC tumorigenic potential in vivo. These results indicate that GGCT, whose expression is promoted by c-Jun, plays an important role in the proliferation and tumorigenic potential of GSCs, and that the phenotype caused by its knockdown is contributed by a decrease in Notch1. Thus, GGCT may represent a novel therapeutic target for attacking GSCs.
据报道,胶质母细胞瘤干细胞(GSCs)通过导致治疗抗性而致使胶质母细胞瘤预后不良。γ-谷氨酰环转移酶(GGCT)在包括胶质母细胞瘤在内的多种癌症类型中高表达,其抑制可抑制癌细胞生长。然而,GGCT过表达的机制及其在GSCs中的功能尚不清楚。在本研究中,我们发现GGCT在从小鼠胶质母细胞瘤模型建立的GSCs中高表达,其敲低可抑制它们的增殖。分析了NRAS及其下游转录因子c-Jun对GGCT表达的影响;NRAS敲低降低了c-Jun和GGCT的表达。c-Jun敲低也降低了GGCT的表达水平并抑制细胞增殖。与此一致,用SP600125对c-Jun进行药理抑制降低了GGCT并抑制了GSC增殖。此外,通过诱变进行的GGCT启动子报告基因分析表明,c-Jun通过AP-1共有序列调节GGCT启动子的活性。基因表达分析显示,GGCT敲低对Delta-Notch途径具有抑制作用,并降低了Notch1的表达。单独敲低Notch1可抑制GSC增殖,证实Notch1在该模型中起作用。Notch1细胞内结构域的强制表达恢复了GGCT敲低的生长抑制作用。此外,GGCT敲低在体内抑制了GSC的致瘤潜力。这些结果表明,其表达由c-Jun促进的GGCT在GSCs的增殖和致瘤潜力中起重要作用,并且其敲低所导致的表型是由Notch1的减少所致。因此,GGCT可能代表攻击GSCs的一个新的治疗靶点。